explore -WSS

explore

author：explore 2025-10-02 21:06:41 - browse：615

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： CDC advisory panel says seniors 'may' get RSV vaccine

WSS

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

CDC advisory panel says seniors 'may' get RSV vaccine

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

AstraZeneca challenges Medicare drug negotiation program

In science, is the line between industry and academia shifting?

FDA panel gives mixed vote on blood pressure devices

leisure time

explore

hotspot

Alkermes shareholders re

In 'major milestone,' FDA approves first cell therapy for solid tumors

Jerome Adams on the need for new antivirals for Covid

Flagship Pioneering startup Sonata Therapeutics lays off 21

ChatGPT in medicine: STAT answers readers' burning questions

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Virginia high school admissions case could be legal follow

Neuroscience startup Neumora files for IPO

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Drug firms test therapies to halt Alzheimer’s before symptoms arise

knowledge

Departing Stanford president retracts two papers

WATCH: Why do our ears pop?

Neuroscience startup Neumora files for IPO

Medicare explains how it will choose drugs for negotiation

Drug firms test therapies to halt Alzheimer’s before symptoms arise

A new drug could help frostbite victims avoid its ravages

explore

leisure time

focus

leisure time